Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer

BACKGROUND: The estrogen receptor (ER) inhibitor tamoxifen reduces breast cancer mortality by 31 % and has served as the standard treatment for ER-positive breast cancers for decades. However, 50 % of advanced ER-positive cancers display de novo resistance to tamoxifen, and acquired resistance evolv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Kangaspeska, Sara, Hultsch, Susanne, Jaiswal, Alok, Edgren, Henrik, Mpindi, John-Patrick, Eldfors, Samuli, Brück, Oscar, Aittokallio, Tero, Kallioniemi, Olli
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4932681/
https://ncbi.nlm.nih.gov/pubmed/27378269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2452-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados